Abstract:Organotypic, three-dimensional (3D) cancer tissue models (OCTM) have enabled investigators to develop predictive markers that can be used in preclinical cancer drug development. However, a drawback of the existing models is that they are mostly based on cell lines based are not physiological. In vitro development of 3D tumoroids using patient derived primary tumors (PDPT) in tumor microenvironment (TME) will have clinical significant and can predict human responses to cancer therapeutics. Here, we describe the generation of OCTM from patient-derived metastatic colorectal cancer, the second most deadly cancer. PDPT were grown in Matrigel for 5 passages and for biobanking purposes tumoroids were further expanded in faCellitate 384 well plates or Sun Bioscience plates to harvest large amounts of well-defined tumoroids cultured for over 21 days. Expanded tumoroids were collected and cryopreserved or gently mixed several times using a pipet tip to break up tumoroids into smaller fragments. These tumor fragments were mixed with endothelial cells, dendritic cells, fibroblasts and embedded in a collagen matrix to simulate TME. The collagen-cell mixture was then added to Transwells and induced to gel to form a collagen gel matrix that simulates TME. The tumoroids were cultured with a specialized medium that supports the growth of complex cell types. The tumor development was monitored daily using bright field microscopy and image analysis was used to monitor tumor size. To evaluate the utility of the OCTM, treatment was initiated at day 10 of the culture period by exposing tissues with the chemotherapeutic drug Cisplatin on days 0, 2, 4, 7, 9, and 11. After each treatment, OCTM tissues (N=2) were fixed for H&E and live/dead staining. Overall, the results of the study showed that: 1) PDPT can be expanded for 5 passages (this low passage number is not expected to change the phenotype of the tumor) and further expanded in high throughput format, 384 well plates, 2) the PDPT could be cultured with multiple cell types in a collagen-gel matrix to recreate the TME, 3) histological evaluation of the OCTM showed a glandular-like tumoroid, 4) immunohistochemical staining revealed that the PDPT in the in vivo-like microenvironment were positive for CK20, and 5) the PDPT shrank following 3 treatment cycles with Cisplatin (day 4). Conclusion: The data shows metastatic colorectal PDPT can be expanded in vitro and cultured in a complex tumor microenvironment on tissue culture inserts. These OCTMs can be used to screen drug safety and efficacy. This study opens new avenues for high-throughput cancer drug screening format using PDPT embedded in a in vivo like TME. This model can be used as a tool for personalized oncology drug testing and for translational assays tailored to other cancer types from our patient derived primary tumor pool. Citation Format: Seyoum Ayehunie, Megan Groves, Bryda Bryda, Alex Armento, Anthony Tolcher. Novel organotypic patient derived primary tumor tissues for oncology drug safety and efficacy studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 221.

Establishment of patient‐derived organotypic tumor spheroid models for tumor microenvironment modeling

Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy

Organoid Models for Precision Cancer Immunotherapy

Establishment of Patient-Derived Tumor Spheroids for Non-Small Cell Lung Cancer

Organoid Modeling of the Tumor Immune Microenvironment

Organoid Models of Tumor Immunology

Immune organoids: from tumor modeling to precision oncology

Abstract 221: Novel organotypic patient derived primary tumor tissues for oncology drug safety and efficacy studies

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold

Patient-Derived Organoids for Precision Cancer Immunotherapy

Organoids: new frontiers in tumor immune microenvironment research

Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer

3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy

Patient-derived organoids in precision cancer medicine

Patient-derived Organoids (pdos) and PDO-derived Xenografts (pdoxs): New Opportunities in Establishing Faithful Pre-Clinical Cancer Models

Colorectal Cancer Tissue-Originated Spheroids Reveal Tumor Intrinsic Signaling Pathways and Mimic Patient Clinical Chemotherapeutic Response As a Rapid and Valid Model

Patient-derived micro-organospheres enable clinical precision oncology

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer